ACQUISITION OF THE ANTIRETROVIRAL PHARMACEUTICAL PRODUCT LAMIVUDINE 500 MG/5 ML SOLUTION 240 ML, FOR SUPPLY OVER A PERIOD OF TWELVE (12) MONTHS

This tender concerns the acquisition of the antiretroviral pharmaceutical product Lamivudine, specifically in a 500 mg/5 ml solution formulation, packaged in 240 ml bottles. The procurement is intended to ensure a consistent supply of this essential medication for a duration of twelve (12) months. The contracting entity responsible for this process is the National Center for the Supply of Strategic Health Resources (CENTRO NACIONAL DE ABASTECIMIENTO DE RECURSOS ESTRATEGICOS EN SALUD - CENARES), which operates under the Ministry of Health (MINSA) of Peru. The procurement is being conducted in the Lima department. This is a Direct Contracting process, identified by the code DIRECTA-DIRECTA-42-2025-CENARES/ MINSA-1, indicating a specific procurement method chosen by the contracting authority. The focus is on securing a reliable source of Lamivudine, a critical component in the treatment of HIV/AIDS, to meet the ongoing needs of the health sector. Interested suppliers are expected to meet the specified quality standards and delivery timelines for this vital pharmaceutical product. The contract aims to guarantee the availability of this medication, ensuring continuity of care for patients requiring antiretroviral therapy.

This is a supplies contract in the governance and public administration sector. Located in Peru, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of PEN 617,520.

Published through Peru SEACE, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.